Strados Labs has acquired the clinical trial division of NuvoAir to strengthen its respiratory research platform, enabling end to end monitoring and advanced endpoint solutions for pharmaceutical and biotech studies.
Glimpse:
Announced in April 2026, the acquisition enhances Strados Labs’ capabilities by adding tools such as spirometry, airway inflammation measurement (FeNO), and electronic clinical outcome assessments (eCOA). The combined platform now supports comprehensive respiratory monitoring across all phases of clinical trials, from Phase I to Phase IV.
Strados Labs, a respiratory health technology company, has acquired the clinical trial business of NuvoAir, marking a significant step in expanding its capabilities in respiratory clinical research. The deal strengthens Strados’ position as a comprehensive provider of endpoint solutions for pharmaceutical and biotech companies conducting respiratory trials.
With this acquisition, Strados Labs now offers a more complete respiratory endpoint suite. The platform combines its existing technologies such as continuous cough monitoring and lung sound analysis with newly added capabilities including spirometry, FeNO (airway inflammation) measurement, and electronic clinical outcome assessments (eCOA).
This integrated approach enables researchers to capture a broader range of respiratory data, including pulmonary function, airway inflammation, and patient reported outcomes, all within a single ecosystem. The result is a more streamlined and efficient clinical trial process with improved data accuracy and patient monitoring.
The combined platform is designed to support respiratory clinical trials across all stages from early phase studies to large scale Phase IV trials offering flexibility for diverse study designs. It also aligns with the growing demand for decentralized and hybrid clinical trials, where remote monitoring plays a critical role.
NuvoAir’s technology, known for enabling remote and location independent data collection, further enhances Strados’ ability to support modern clinical trial models. This allows participants to contribute high quality health data from home, improving accessibility and patient experience in trials.
The acquisition reflects a broader industry trend toward integrating multiple diagnostic and monitoring tools into unified platforms, enabling more comprehensive insights into respiratory diseases such as asthma, COPD, and other chronic conditions.
Overall, this strategic move positions Strados Labs as a key player in the evolving clinical trial landscape, where advanced analytics, remote monitoring, and integrated data systems are becoming essential for accelerating drug development and improving outcomes.
“Delivering full spectrum respiratory endpoint solutions for life sciences.”
By
HB Team
Related News
